

Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQX: LVCLY

ASX ANNOUNCEMENT

Extension of Rights Issue

Sydney, Australia & Auckland, New Zealand, 9 December 2021 – Living Cell Technologies (**LCT** or **Company**) advises that the Closing Date for its Renounceable Rights Issue announced on 15 November 2021 has been extended by one week to 21 December 2021 at 5.00pm Sydney time.

The Rights Issue is for 2 New Shares for every 3 Shares held on the Record Date and 1 New Option for every 3 New shares issued at an issue price of \$0.008 for each New Share and one third of a New Option. Shareholders are referred to the Company's prospectus, a copy may be obtained from the Company's website at www.lctglobal.com.

The amended timetable is set out below:

Event	Date
Closing Date of Offer 5.00pm (Sydney time)	21 December 2021
Company to Announce Results of Offer	24 December 2021
Allotment of Securities Deferred Settlement Trading Ends	30 December 2021
Despatch Date Expected date for normal trading of securities to commence on ASX	4 January 2022

The amended timetable is indicative only and subject to change. The Company in consultation with 180 Markets, as broker to the issue, reserves the right to further vary the above dates, subject to the Listing Rules and the Corporations Act.

Eligible Shareholders who wish to participate in the Offer should refer to your personalised instructions on your Entitlement and Acceptance Form available online at lctOffer2021.thereachagency.com

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

<p>At the Company: Bernie Tuch Chief Executive Mobile: +61 411 461 604 bernietuch@lctglobal.com</p>	<p>At the Company: Mark Licciardo Mertons Corporate Services Pty Ltd P: +61 3 8689 9997 markl@mertons.com.au</p>
--	---

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that has focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. LCT has secured initial funding for a third clinical with NTCELL (alginate coated capsule containing clusters of neonatal porcine choroid plexus cells) after completing phase IIa and IIb clinical studies in Parkinson's disease. In a Phase IIb trial of NTCELL, there was not a statistically significant difference between the groups who received NTCELL and the placebo group at the 26-week study endpoint. However, at 24 months post-implant a clinically relevant effect was observed (<-6.45 points from baseline) in two of the three treatment groups. In the third clinical trial LCT will seek to alter the rate of disease progression in early-to-mid stage Parkinson's disease. LCT has out-licensed DIABECCELL (alginate coated capsule containing neonatal porcine pancreatic cells) to Diatrax Otsuka Limited to continue the development of a cell therapy for type 1 diabetes in return for a royalty arrangement. LCT continues to seek new product project opportunities and also interactions that leverage its financial assets. LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.